Cover Image
Market Research Report
Product code 
912656

Analgesics

Published: | Global Industry Analysts, Inc. | 482 Pages | Delivery time: 1-2 business days

Price

Back to Top
Analgesics
Published: April 1, 2021
Global Industry Analysts, Inc.
Content info: 482 Pages
Delivery time: 1-2 business days
  • ALL
  • Description
  • Table of Contents
Description

Abstract:

Global Analgesics Market to Reach $59.2 Billion by 2026

Pain management continues to be one of the most sought-after treatment options for patients within the healthcare arena that underscores the critical significance of analgesics. Analgesics are drugs meant for pain control primarily. The drugs work on the CNS and peripheral nervous system for reducing or blocking pain sensitivity. There are also analgesics which work by preventing creation of pain mediating chemicals in the body. Widely used for treatment of mild to acute pain attributed to several medical conditions, injuries, surgeries and terminal disorders, analgesics have ruled the pain management domain for the past several decades. These medications have provided medical practitioners with an effective option to alleviate pain and help improve quality of life for patients. Amid the COVID-19 crisis, the global market for Analgesics estimated at US$45.1 Billion in the year 2020, is projected to reach a revised size of US$59.2 Billion by 2026, growing at a CAGR of 4.7% over the analysis period. Prescription, one of the segments analyzed in the report, is projected to grow at a 4.4% CAGR to reach US$37.7 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the OTC segment is readjusted to a revised 5.1% CAGR for the next 7-year period. This segment currently accounts for a 38.2% share of the global Analgesics market.

The U.S. Market is Estimated at $15.2 Billion in 2021, While China is Forecast to Reach $8.2 Billion by 2026

The Analgesics market in the U.S. is estimated at US$15.2 Billion in the year 2021. The country currently accounts for a 32.76% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$8.2 Billion in the year 2026 trailing a CAGR of 6.5% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.3% and 3.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR while Rest of European market (as defined in the study) will reach US$8.8 Billion by the close of the analysis period.

Growth in these markets are benefiting from increasing incidence of diseases like cancer, arthritis, CVD, and also other acute and chronic diseases which causes severe pain. Cancer pain, neuropathic pain, post-operative pain, and lower back pain represent the important market segments. Increasing incidence of cancer globally is poised to be a key driving force for market growth. Further, increasing prevalence of chronic diseases has also fostered the use of pain management therapeutics. Increasing innovation in the area, owing to increased research investment by drug development companies, for advancing combination of compounds for developing new and more effective analgesics with enhanced efficacy as well as fewer side effects, is another prominent factor contributing towards market growth.

Opioids Segment to Reach $18.4 Billion by 2026

Opioid analgesic drugs represent the gold standard in pain relieving treatment of critically ill patients across disease segments, including COVID-19. Fentanyl, morphine, and hydromorphone are among the most commonly used IV opioid analgesic drugs in the ICU settings for COVID as well as non-COVID patients. Global Opioids segment is estimated at US$14.9 Billion in 2020, and is projected to reach US$18.4 Billion by 2026 reflecting a compounded annual growth rate of 3.7% over the analysis period. United States constitutes the largest regional market for Opioids segment, accounting for 29.9% of the global sales in 2020. China is poised to register the fastest compounded annual growth rate of 5.2% over the analysis period, to reach US$2.6 Billion by 2026.

Select Competitors (Total 146 Featured) -

  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Endo Pharmaceuticals, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Novartis International AG
  • Pfizer, Inc.
  • Reckitt Benckiser Group PLC
  • Sanofi
Table of Contents
Product Code: MCP-5064

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • A Prelude to Analgesics
    • Analgesics: Perfect Therapeutic Options to Solve Mild to Crippling Pain
    • Key Segments
    • Opioid Analgesics
    • Non-Opioid Analgesics
    • NSAIDs
    • Topical NSAIDs
    • Others
    • Acetaminophen
    • Adjuvant Analgesics
    • Impact of COVID-19 on Analgesics
    • NSAIDs
    • NSAIDs Tend to Decrease Effectiveness of COVID-19 Vaccines, States a Yale University Study
    • Opioid
    • Acetaminophen
    • Global Analgesics Market to Witness Rapid Growth
    • Drugs Indicated for Pain Management
    • The US and Europe Represent the Largest Regions, Asia-Pacific to Witness fastest Growth
    • Non-Opioids: Fastest Growing Category
    • Competition
    • Recent Market Activity
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Aging Population & Increasing Burden of Chronic Diseases Drives Market
    • EXHIBIT 1: Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
    • EXHIBIT 2: Fatalities by Heart Conditions: Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
    • EXHIBIT 3: Rising Diabetes Prevalence Presents Opportunity for Cell Surface Markers: Number of Adults (20-79) with Diabetes (in Millions) by Region for 2017 and 2045
    • Growing Incidence of Cancer and the Associated Pain to Drive the Analgesics Market
    • EXHIBIT 4: Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
    • EXHIBIT 5: Global Number of New Cancer Cases and Cancer-related Deaths by Cancer Site for 2018
    • EXHIBIT 6: Number of New Cancer Cases and Deaths (in Million) by Region for 2018
    • Advancements in Design and Delivery of Analgesic Drugs
    • Development of Safer Opioids with More Safer Profiles
    • Drug Pipeline with Efficacious Drugs
    • OTC Analgesics Market to Witness Fastest Growth
    • Topical Analgesics Market Holds Significant Share
    • Combination Therapies Gain Prominence
    • A Few Novel Analgesic Products under Development
    • E-commerce Platforms Strengthen Pharmaceutical Distribution in Crisis Period
    • Neuropathic Pain Management: Market with High Potential
    • Migraine Market: A Core Vertical in CNS Pain Management
    • Migraine Care: Select Patent Expiries (2013-2015)
    • Reyvow, Eli Lilly's Novel Migraine Drug with the Potential to Lead the Global Migraine Medications Market
    • Three New Migraine Drugs Obtain FDA Approval
    • Eli Lilly's Emgality Receives FDA Approval
    • Increasing Cases of Peripheral Nerve Injuries Drive the Analgesics Market
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Analgesics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Analgesics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Analgesics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Prescription by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Prescription by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Prescription by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for OTC by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for OTC by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for OTC by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Opioids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Opioids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Opioids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for NSAIDs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for NSAIDs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for NSAIDs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 19: World Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 20: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 21: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 22: World Current & Future Analysis for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 23: World Historic Review for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 24: World 15-Year Perspective for Parenteral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 25: World Current & Future Analysis for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 26: World Historic Review for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 27: World 15-Year Perspective for Topical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 28: World Current & Future Analysis for Transdermal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 29: World Historic Review for Transdermal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 30: World 15-Year Perspective for Transdermal by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 31: World Current & Future Analysis for Rectal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 32: World Historic Review for Rectal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 33: World 15-Year Perspective for Rectal by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 34: USA Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 35: USA Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 36: USA 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2012, 2020 & 2027
    • TABLE 37: USA Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 38: USA Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 39: USA 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2012, 2020 & 2027
    • TABLE 40: USA Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 41: USA Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 42: USA 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 43: Canada Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 44: Canada Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 45: Canada 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2012, 2020 & 2027
    • TABLE 46: Canada Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 47: Canada Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 48: Canada 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2012, 2020 & 2027
    • TABLE 49: Canada Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 50: Canada Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 51: Canada 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 52: Japan Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 53: Japan Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 54: Japan 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2012, 2020 & 2027
    • TABLE 55: Japan Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 56: Japan Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 57: Japan 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2012, 2020 & 2027
    • TABLE 58: Japan Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 59: Japan Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 60: Japan 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 61: China Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 62: China Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 63: China 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2012, 2020 & 2027
    • TABLE 64: China Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 65: China Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 66: China 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2012, 2020 & 2027
    • TABLE 67: China Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 68: China Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 69: China 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 70: Europe Current & Future Analysis for Analgesics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 71: Europe Historic Review for Analgesics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 72: Europe 15-Year Perspective for Analgesics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 73: Europe Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 74: Europe Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 75: Europe 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2012, 2020 & 2027
    • TABLE 76: Europe Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 77: Europe Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 78: Europe 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2012, 2020 & 2027
    • TABLE 79: Europe Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 80: Europe Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 81: Europe 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 82: France Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 83: France Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 84: France 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2012, 2020 & 2027
    • TABLE 85: France Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 86: France Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 87: France 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2012, 2020 & 2027
    • TABLE 88: France Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 89: France Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 90: France 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 91: Germany Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 92: Germany Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 93: Germany 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2012, 2020 & 2027
    • TABLE 94: Germany Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 95: Germany Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 96: Germany 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2012, 2020 & 2027
    • TABLE 97: Germany Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 98: Germany Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 99: Germany 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 100: Italy Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 101: Italy Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 102: Italy 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2012, 2020 & 2027
    • TABLE 103: Italy Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 104: Italy Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 105: Italy 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2012, 2020 & 2027
    • TABLE 106: Italy Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 107: Italy Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 108: Italy 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 109: UK Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 110: UK Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 111: UK 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2012, 2020 & 2027
    • TABLE 112: UK Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 113: UK Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 114: UK 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2012, 2020 & 2027
    • TABLE 115: UK Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 116: UK Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 117: UK 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2012, 2020 & 2027
  • SPAIN
    • TABLE 118: Spain Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 119: Spain Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 120: Spain 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2012, 2020 & 2027
    • TABLE 121: Spain Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 122: Spain Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 123: Spain 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2012, 2020 & 2027
    • TABLE 124: Spain Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 125: Spain Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 126: Spain 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2012, 2020 & 2027
  • RUSSIA
    • TABLE 127: Russia Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 128: Russia Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 129: Russia 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2012, 2020 & 2027
    • TABLE 130: Russia Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 131: Russia Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 132: Russia 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2012, 2020 & 2027
    • TABLE 133: Russia Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 134: Russia Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 135: Russia 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 136: Rest of Europe Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 137: Rest of Europe Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 138: Rest of Europe 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2012, 2020 & 2027
    • TABLE 139: Rest of Europe Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 140: Rest of Europe Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 141: Rest of Europe 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2012, 2020 & 2027
    • TABLE 142: Rest of Europe Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 143: Rest of Europe Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 144: Rest of Europe 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 145: Asia-Pacific Current & Future Analysis for Analgesics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 146: Asia-Pacific Historic Review for Analgesics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 147: Asia-Pacific 15-Year Perspective for Analgesics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027
    • TABLE 148: Asia-Pacific Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 149: Asia-Pacific Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 150: Asia-Pacific 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2012, 2020 & 2027
    • TABLE 151: Asia-Pacific Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 152: Asia-Pacific Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 153: Asia-Pacific 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2012, 2020 & 2027
    • TABLE 154: Asia-Pacific Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 155: Asia-Pacific Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 156: Asia-Pacific 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2012, 2020 & 2027
  • AUSTRALIA
    • TABLE 157: Australia Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 158: Australia Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 159: Australia 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2012, 2020 & 2027
    • TABLE 160: Australia Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 161: Australia Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 162: Australia 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2012, 2020 & 2027
    • TABLE 163: Australia Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 164: Australia Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 165: Australia 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2012, 2020 & 2027
  • INDIA
    • TABLE 166: India Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 167: India Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 168: India 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2012, 2020 & 2027
    • TABLE 169: India Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 170: India Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 171: India 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2012, 2020 & 2027
    • TABLE 172: India Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 173: India Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 174: India 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2012, 2020 & 2027
  • SOUTH KOREA
    • TABLE 175: South Korea Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 176: South Korea Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 177: South Korea 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2012, 2020 & 2027
    • TABLE 178: South Korea Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 179: South Korea Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 180: South Korea 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2012, 2020 & 2027
    • TABLE 181: South Korea Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 182: South Korea Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 183: South Korea 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2012, 2020 & 2027
  • REST OF ASIA-PACIFIC
    • TABLE 184: Rest of Asia-Pacific Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 185: Rest of Asia-Pacific Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 186: Rest of Asia-Pacific 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2012, 2020 & 2027
    • TABLE 187: Rest of Asia-Pacific Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 188: Rest of Asia-Pacific Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 189: Rest of Asia-Pacific 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2012, 2020 & 2027
    • TABLE 190: Rest of Asia-Pacific Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 191: Rest of Asia-Pacific Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 192: Rest of Asia-Pacific 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2012, 2020 & 2027
  • LATIN AMERICA
    • TABLE 193: Latin America Current & Future Analysis for Analgesics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 194: Latin America Historic Review for Analgesics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 195: Latin America 15-Year Perspective for Analgesics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2020 & 2027
    • TABLE 196: Latin America Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 197: Latin America Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 198: Latin America 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2012, 2020 & 2027
    • TABLE 199: Latin America Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 200: Latin America Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 201: Latin America 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2012, 2020 & 2027
    • TABLE 202: Latin America Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 203: Latin America Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 204: Latin America 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2012, 2020 & 2027
  • ARGENTINA
    • TABLE 205: Argentina Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 206: Argentina Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 207: Argentina 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2012, 2020 & 2027
    • TABLE 208: Argentina Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 209: Argentina Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 210: Argentina 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2012, 2020 & 2027
    • TABLE 211: Argentina Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 212: Argentina Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 213: Argentina 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2012, 2020 & 2027
  • BRAZIL
    • TABLE 214: Brazil Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 215: Brazil Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 216: Brazil 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2012, 2020 & 2027
    • TABLE 217: Brazil Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 218: Brazil Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 219: Brazil 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2012, 2020 & 2027
    • TABLE 220: Brazil Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 221: Brazil Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 222: Brazil 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2012, 2020 & 2027
  • MEXICO
    • TABLE 223: Mexico Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 224: Mexico Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 225: Mexico 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2012, 2020 & 2027
    • TABLE 226: Mexico Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 227: Mexico Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 228: Mexico 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2012, 2020 & 2027
    • TABLE 229: Mexico Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 230: Mexico Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 231: Mexico 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2012, 2020 & 2027
  • REST OF LATIN AMERICA
    • TABLE 232: Rest of Latin America Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 233: Rest of Latin America Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 234: Rest of Latin America 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2012, 2020 & 2027
    • TABLE 235: Rest of Latin America Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 236: Rest of Latin America Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 237: Rest of Latin America 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2012, 2020 & 2027
    • TABLE 238: Rest of Latin America Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 239: Rest of Latin America Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 240: Rest of Latin America 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2012, 2020 & 2027
  • MIDDLE EAST
    • TABLE 241: Middle East Current & Future Analysis for Analgesics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 242: Middle East Historic Review for Analgesics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 243: Middle East 15-Year Perspective for Analgesics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2020 & 2027
    • TABLE 244: Middle East Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 245: Middle East Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 246: Middle East 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2012, 2020 & 2027
    • TABLE 247: Middle East Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 248: Middle East Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 249: Middle East 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2012, 2020 & 2027
    • TABLE 250: Middle East Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 251: Middle East Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 252: Middle East 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2012, 2020 & 2027
  • IRAN
    • TABLE 253: Iran Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 254: Iran Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 255: Iran 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2012, 2020 & 2027
    • TABLE 256: Iran Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 257: Iran Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 258: Iran 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2012, 2020 & 2027
    • TABLE 259: Iran Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 260: Iran Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 261: Iran 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2012, 2020 & 2027
  • ISRAEL
    • TABLE 262: Israel Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 263: Israel Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 264: Israel 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2012, 2020 & 2027
    • TABLE 265: Israel Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 266: Israel Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 267: Israel 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2012, 2020 & 2027
    • TABLE 268: Israel Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 269: Israel Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 270: Israel 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2012, 2020 & 2027
  • SAUDI ARABIA
    • TABLE 271: Saudi Arabia Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 272: Saudi Arabia Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 273: Saudi Arabia 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2012, 2020 & 2027
    • TABLE 274: Saudi Arabia Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 275: Saudi Arabia Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 276: Saudi Arabia 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2012, 2020 & 2027
    • TABLE 277: Saudi Arabia Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 278: Saudi Arabia Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 279: Saudi Arabia 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2012, 2020 & 2027
  • UNITED ARAB EMIRATES
    • TABLE 280: UAE Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 281: UAE Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 282: UAE 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2012, 2020 & 2027
    • TABLE 283: UAE Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 284: UAE Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 285: UAE 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2012, 2020 & 2027
    • TABLE 286: UAE Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 287: UAE Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 288: UAE 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2012, 2020 & 2027
  • REST OF MIDDLE EAST
    • TABLE 289: Rest of Middle East Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 290: Rest of Middle East Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 291: Rest of Middle East 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2012, 2020 & 2027
    • TABLE 292: Rest of Middle East Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 293: Rest of Middle East Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 294: Rest of Middle East 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2012, 2020 & 2027
    • TABLE 295: Rest of Middle East Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 296: Rest of Middle East Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 297: Rest of Middle East 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2012, 2020 & 2027
  • AFRICA
    • TABLE 298: Africa Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 299: Africa Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 300: Africa 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2012, 2020 & 2027
    • TABLE 301: Africa Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 302: Africa Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 303: Africa 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2012, 2020 & 2027
    • TABLE 304: Africa Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 305: Africa Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 306: Africa 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 146